Printer Friendly

GENETICS INSTITUTE AND AMERICAN HOME PRODUCTS TO COLLABORATE IN SMALL MOLECULE DRUG DISCOVERY

 GENETICS INSTITUTE AND AMERICAN HOME PRODUCTS TO
 COLLABORATE IN SMALL MOLECULE DRUG DISCOVERY
 CAMBRIDGE, Mass., March 3 /PRNewswire/ -- Genetics Institute, Inc. (NASDAQ: GENI) and American Home Products Corporation (NYSE: AHP) announced today a new collaboration for the discovery and development of new small molecule-based drugs.
 The agreement provides the parties with an opportunity to benefit from complementary capabilities in new drug discovery by combining Genetics Institute's expertise in molecular biology and assay development with the expertise of Wyeth-Ayerst, the pharmaceutical division of AHP, in synthetic chemistry and pharmaceutical development.
 Initially the collaboration is expected to be focused in the area of cellular adhesion. Cellular adhesion proteins play a critical role in the movement of white blood cells out of the blood stream into surrounding tissue. By blocking the action of these proteins with appropriate small molecule agents, the companies' scientists believe that they may have the ability to develop potential new treatments for a wide range of disorders such as rheumatoid arthritis, asthma, organ transplant rejection and adult respiratory distress syndrome.
 The agreement provides for significant funding to Genetics Institute over the next several years. It also provides for shared marketing rights for any products resulting from the collaboration.
 "This collaboration builds on our strengths in using proteins as targets for drug discovery as well as our long-standing interest in cellular adhesion," said Dr. Patrick Gage, executive vice president of Genetics Institute.
 "We are optimistic that successful new pharmaceuticals will result from this research program," said Fred Hassan, president of Wyeth-Ayerst Laboratories.
 Genetics Institute is a leading biopharmaceutical firm engaged in the discovery and development of human pharmaceuticals through recombinant DNA and other technologies. The company has a diversified portfolio of licensed and proprietary pharmaceutical products at various stages of development, including treatments for anemia, hemophilia, cancer, infectious disease, bone damage, heart disease, inflammatory conditions and immune system disorders. AHP is a majority shareholder in Genetics Institute and has an option to purchase all, but not less than all, of the outstanding shares of Genetics Institute stock on predefined terms over a five year option period.
 American Home Products Corporation is a worldwide manufacturer and marketer of prescription drugs, medical supplies and diagnostics, over-the-counter medicines and food products. Its Wyeth-Ayerst division is a major research-oriented pharmaceutical company with leading product s in the areas of female health care, cardiovascular and metabolic disease therapies, central nervous system drugs, anti-inflammatory agents, vaccines and infant nutritionals.
 -0- 3/3/92
 /CONTACT: Melinda Lindquist of Genetics Institute, 617-876-1170; or Audrey Ashby of Wyeth-Ayerst Laboratories, 215-971-5823/
 (GENI AHP) CO: Genetics Institute Inc.; American Home Products Corporation ST: Massachusetts IN: MTC SU:


EG -- NE018 -- 4638 03/03/92 16:36 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 3, 1992
Words:445
Previous Article:AIM STRATEGIC INCOME FUND DIVIDEND DECLARATION FOR THE MONTH OF MARCH 1992
Next Article:MICROLOG SHOWS BEST RESULTS IN SIX QUARTERS
Topics:


Related Articles
GENETICS INSTITUTE ANNOUNCES OUTCOME OF CONVERTIBLE EXCHANGEABLE PREFERRED STOCK REDEMPTION
PATRICK GAGE, PH.D. TO BECOME GENETICS INSTITUTE'S CHIEF OPERATING OFFICER; OTHER OFFICERS APPOINTED
GENETICS INSTITUTE AND THE JOHNS HOPKINS UNIVERSITY COOPERATE TO FORM NEW COMPANY
GENETICS INSTITUTE PROPOSES ACQUISITION OF SCIGENICS
MILLENNIUM AND AMERICAN HOME PRODUCTS SIGN BROAD CENTRAL NERVOUS SYSTEM DRUG DISCOVERY AND TECHNOLOGY ALLIANCE
Wyeth-Ayerst Acquires International Rights to Commercialize New Oncology Product
Genetics Institute and Chugai Sign Functional Genomics Agreement
Genetics Institute and Affymetrix Sign New Agreement and Extend GeneChip(R) Technology Access to DiscoverEase(R) Participants
Neurotrophic Bioscience Inc. Signs DiscoverEase(R) Agreement.
American Home and Targeted Genetics establish partnership for B-domain deleted factor VIII hemophilia gene Therapy.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters